Better Space Stock to Buy Before 2026 Runs Out: SpaceX vs. Rocket Lab

SpaceX is shown as the dominant U.S. launch provider (255 launches since 2025 vs. Rocket Lab’s 35), with SpaceX’s Falcon 9 (22,800kg to LEO) and planned Starship offering larger capacity, while Rocket Lab focuses on smaller/medium-lift (Electron ~300kg; Neutron planned to reach 13,000kg). The article frames Rocket Lab as the “better buy” for pure-play space exposure, citing Rocket Lab’s $602M revenue vs. SpaceX’s $18.7B, but both trade at steep price-to-sales multiples (SpaceX ~110x; Rocket Lab ~82x). Rocket Lab’s deal to acquire Iridium Communications for $8B is highlighted as a key step to expand its vertically integrated constellation business.

Analysis

The key market mechanism is not “space TAM” but concentration of launch supply. A single dominant provider can support premium pricing until customers, especially defense and sovereign buyers, decide concentration risk is too high; that is the opening for RKLB. The near-term issue is that launch is still a credibility business, so any slip in Neutron timing would push RKLB back toward being valued as a mixed hardware/software subcontractor rather than a true launch franchise.

For SPCX, the equity story is increasingly a bundle of adjacent optionalities, not core launch economics. That matters because the multiple is only defensible if investors continue to underwrite non-launch revenue acceleration; if AI/Starlink monetization stalls, the valuation can de-rate fast even if launch cadence stays strong. Second-order winners are satellite component suppliers and defense integrators that can sell to multiple launch ecosystems; second-order losers are smaller launch peers with limited cadence and no systems layer to cushion margin volatility.

The IRDM angle is more interesting as an event-driven spread than as a long-term industrial thesis. If the transaction is stock-heavy, RKLB inherits integration and dilution risk before any synergy shows up, while IRDM holders get optionality on the buyer’s execution; if the terms are cash-heavy, the financing burden becomes the real risk. The contrarian read is that the market may be overpaying for “pure-play” scarcity while underestimating how quickly launch commoditizes once a reliable alternative exists.

Catalysts over 1-3 months are Neutron milestones and any definitive acquisition terms; over 6-18 months the question is whether RKLB can prove repeatable medium-lift cadence. Falsifiers: a delayed Neutron launch, a widening gap between RKLB bookings and launches, or a deal structure that forces excessive dilution.

Key Decisions for Investors

• Avoid chasing RKLB at current multiples; wait for a Neutron flight-date confirmation before adding size. If the program slips, expect a 15-25% multiple reset over 1-3 months as the market re-prices it as a services company, not a launch peer.
• If the IRDM transaction is confirmed with fixed terms, set up an event-driven long IRDM / short RKLB pair only if the spread widens beyond 8-10% to compensate for closing risk; this is a cleaner expression than betting on the launch narrative.
• Use SPCX only as a high-beta basket expression, not a core fundamental long. The trade is best on pullbacks if satellite monetization data improves; otherwise the multiple is vulnerable to compression if non-launch growth disappoints.
• Relative-value watch item: favor satellite systems and defense integrators with multi-launch optionality over pure launch names until Neutron proves itself; this is a months-long thesis, not a days-long catalyst.